Ah, the stock market. A bastion of rational expectation, meticulous forecasting, and, occasionally, the wild, unpredictable pronouncements of a certain former (and potentially future) President. Donald J. Trump, a man whose approach to policy often resembles a game of economic roulette, continues to keep investors, analysts, and anyone with a passing interest in their retirement fund on their toes. Forget the “Art of the Deal”; we’re living through the “Art of the Market Mayhem,” where a single Truth Social post can send sectors scrambling and analysts reaching for their strongest coffee.
The latest flurry of announcements, threats, and policy pivots from the Trump orbit has once again demonstrated that when it comes to market stability, predictability is for the faint of heart. From tariffs that bite, to healthcare policy that shapeshifts, and even musings on soda recipes, the market’s reaction is less about fundamental analysis and more about deciphering the latest tweet-storm or rally cry. Let’s dive into the glorious chaos.
The Tariff Tango: A Two-Step of Uncertainty
Tariffs, the economic equivalent of a blunt instrument, remain a cornerstone of the Trump playbook. Take, for instance, the saga of John Deere (DE). The agricultural giant found itself squarely in the crosshairs when Trump threatened a colossal 200% tariff on its products if the company dared to move manufacturing to Mexico. This pronouncement, aimed at protecting American jobs, initially sent Deere shares tumbling over 2% in after-hours trading on September 23, 2024. Fast forward to November 26, 2025, and the company was forecasting an annual profit below estimates, explicitly citing a pre-tax tariff impact of nearly $600 million in 2025, which saw its shares fall 4% in premarket trading. Yet, in a twist that would make a telenovela writer proud, Deere was also reported to be up more than 4% in the week following the initial threat in September 2024, and 9% over the preceding three months, with some analysts even issuing a “BUY” recommendation. It appears the market, much like a seasoned poker player, sometimes calls a bluff, or at least finds other reasons to be optimistic amidst the bluster.
Then there’s the pharmaceutical industry, a sector that routinely finds itself under the microscope. On September 26, 2025, President Trump announced a 100% levy on imported “branded or patented Pharmaceutical Product” set to take effect from October 1, 2025. This followed earlier threats of tariffs as high as 250%. One might expect a pharmaceutical market meltdown, but alas, the devil, as always, was in the details. The tariffs came with a rather generous carve-out: companies actively building manufacturing plants in the U.S. would be exempt. Consequently, major U.S. drugmakers like Merck (MRK), Eli Lilly (LLY), and Johnson & Johnson (JNJ) actually saw their shares *rise* less than 1% on September 26, 2025, slightly outperforming the broader S&P 500 index. Analysts from BMO Capital Markets and Jefferies quickly noted that the tariffs were “unlikely to apply to any of our coverage” given the existing or planned U.S. production facilities. European and Asian pharmaceutical stocks, however, were not so fortunate, experiencing declines. It seems even a 100% tariff can be a win for some, provided they’ve already invested billions in domestic manufacturing.
Hollywood’s Blockbuster Blunder
Never one to shy away from a dramatic announcement, President Trump took aim at the global entertainment industry. On May 5, 2025, he unveiled a sweeping 100% tariff on all movies produced outside the U.S., declaring on Truth Social that the American film industry was “dying a ‘very fast death'”. The rationale? Other countries were “stealing candy from a baby” by offering incentives to lure productions away.
The market’s reaction was, predictably, less enthusiastic than a standing ovation. American media stocks promptly fell. Netflix (NFLX), a company heavily reliant on its global production network, saw its shares tumble 2.5% in early trading, and 4.9% in premarket action. Other industry titans like Disney (DIS), Warner Bros Discovery (WBD), and Universal-owner Comcast (CMCSA) experienced declines ranging from 0.7% to 2.7%. Even theater operators such as Cinemark (CNK) and IMAX (IMAX) were not spared, dropping 5.4% and 5.9% respectively. Analysts were quick to point out the obvious: “There is too much uncertainty, and this latest move raises more questions than answers,” noted PP Foresight analyst Paolo Pescatore. Rosenblatt Securities analyst Barton Crockett warned that “raising the cost to produce movies could lead studios to make less content” and risked “retaliatory tariffs against American content overseas”. The prospect of a global cinematic trade war, it seems, is less appealing than a summer blockbuster.
Healthcare’s High-Wire Act
If there’s one area where policy flip-flops are practically an Olympic sport, it’s healthcare. The Affordable Care Act (ACA), or Obamacare, continues to be a favorite target, even as its subsidies prove surprisingly resilient. On November 27, 2025, Trump initially admitted he’d “rather not” extend Obamacare subsidies past the year. However, in a swift pivot, the White House was soon reportedly preparing to pitch a Trump Obamacare extension, albeit “with limits”. Later, Trump himself stated an extension “may be necessary,” only to immediately add, “I’d rather not extend them at all”. The market, ever the optimist, chose to focus on the “may be necessary” part.
This policy whiplash had a tangible impact on health insurance stocks. On November 24, 2025, reports of a potential extension sent shares soaring. Molina Healthcare (MOH) climbed over 3%, Centene (CNC) jumped 5%, and Oscar Health (OSCR) dramatically surged 18%. Elevance Health (ELV) gained over $20 a share, and UnitedHealth Group (UNH) was up 5% in the week leading up to November 26, 2025. This positive reaction stands in stark contrast to earlier in November. On November 10, 2025, health insurers had slid between 2% and 10% in premarket trading after a deal to end a government shutdown *without* extending ACA subsidies. During that period, Centene (CNC) plummeted 9.8%, Molina Healthcare (MOH) slipped 4.9%, and Elevance Health (ELV) was down 2%. Trump’s own Truth Social post on November 10, 2025, calling the subsidies a “windfall for Health Insurance Companies, and a DISASTER for the American people,” certainly didn’t help stabilize investor sentiment. Analysts like Ann Hynes of Mizuho Securities USA, however, saw a two-year extension as “favorable” for managed care companies, highlighting the constant need to interpret the political tea leaves.
Geopolitical Grandstanding and Global Ripples
Beyond domestic policy, Trump’s foreign policy pronouncements continue to send ripples, or at least confused shrugs, across global markets. His announcement on November 28, 2025, of a “land operation against ‘drug trafficking’ in Venezuela” certainly grabbed headlines. However, immediate market reactions, particularly in oil prices or defense stocks, were not distinctly evident in the latest data, suggesting either a wait-and-see approach or a market fatigued by geopolitical drama.
More concrete, however, were his actions regarding South Africa. Following a G20 summit in Johannesburg that the U.S. delegation boycotted, Trump announced on November 26, 2025, that he was “barring South Africa from participating in the Group of 20 summit next year” in Miami and would “stop all payments and subsidies” to the country. This was reportedly due to South Africa’s refusal to hand over G20 hosting responsibilities to a junior U.S. official and unsubstantiated claims of persecution against Afrikaners. To add insult to injury, a 30% “reciprocal” tariff was also imposed on South African exports. Analysts were quick to warn of a significant impact on South Africa’s economy and the potential for an “investment strike from US companies”. While specific U.S. stock market data tied directly to this latest escalation was not immediately available, the message to companies with South African exposure was unmistakably grim.
On a more positive note for some sectors, a report on November 27, 2025, indicated that the Trump administration was negotiating a Taiwan trade deal aimed at boosting the U.S. semiconductor industry. While this news holds significant potential for companies like TSMC (TSM), NVIDIA (NVDA), and Intel (INTC), specific market reactions or analyst comments directly attributable to *this particular report* were not yet widely published, likely due to its recency.
Truth Social’s Market Musings
Finally, we cannot overlook the unique channel through which many of these market-moving (or market-ignoring) pronouncements are delivered: Truth Social. Beyond the serious policy declarations, the platform also hosts more whimsical, yet equally official, presidential thoughts. Case in point: Trump’s claim on November 27, 2025, that Coca-Cola (KO) would be changing its recipe to cane sugar. Despite the authoritative tone, the market, perhaps wisely, largely ignored this particular pronouncement, as no discernible stock price movement for Coca-Cola (KO) was observed. It seems even the most ardent followers draw a line at beverage formulations.
In conclusion, the stock market under the influence of Donald Trump remains a fascinating, if somewhat bewildering, spectacle. Investors are tasked not just with analyzing balance sheets and economic indicators, but also with interpreting the latest policy pronouncements, often delivered with a flourish of contradictions and a healthy dose of bravado. The only certainty, it seems, is the enduring uncertainty, ensuring that market participants will continue to experience a daily dose of economic whiplash, all while trying to discern the signal from the noise.
DISCLAIMER: We read Trump’s posts so you don’t have to. This is comedy meets market data, not financial advice. Not political advice either – we just like charts and chaos.
Elana Harper is a seasoned financial editor and market analyst with over a decade of experience covering global equities, economic trends, and corporate earnings. Known for her sharp insights, Elana specializes in making complex financial topics accessible to a broad audience. She now serves as the Senior Financial Editor at Stock Market Watch, where she oversees daily market coverage and political commentary.